CA2902841A1 - Methods and compositions for detecting pancreatic cancer - Google Patents

Methods and compositions for detecting pancreatic cancer Download PDF

Info

Publication number
CA2902841A1
CA2902841A1 CA2902841A CA2902841A CA2902841A1 CA 2902841 A1 CA2902841 A1 CA 2902841A1 CA 2902841 A CA2902841 A CA 2902841A CA 2902841 A CA2902841 A CA 2902841A CA 2902841 A1 CA2902841 A1 CA 2902841A1
Authority
CA
Canada
Prior art keywords
pancreatic cancer
protein
level
cancer biomarker
homo sapiens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2902841A
Other languages
English (en)
French (fr)
Inventor
Lewis K. Pannell
Jana ROCKER
Jack DI PALMA
Carlo Contreras
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Creatics LLC
Original Assignee
Creatics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creatics LLC filed Critical Creatics LLC
Publication of CA2902841A1 publication Critical patent/CA2902841A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2902841A 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer Abandoned CA2902841A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361780574P 2013-03-13 2013-03-13
US61/780,574 2013-03-13
PCT/US2014/026857 WO2014160499A2 (en) 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer

Publications (1)

Publication Number Publication Date
CA2902841A1 true CA2902841A1 (en) 2014-10-02

Family

ID=50933479

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2902841A Abandoned CA2902841A1 (en) 2013-03-13 2014-03-13 Methods and compositions for detecting pancreatic cancer

Country Status (7)

Country Link
US (3) US20160033511A1 (enExample)
EP (1) EP2972375A2 (enExample)
JP (3) JP6646571B2 (enExample)
AU (3) AU2014243704A1 (enExample)
CA (1) CA2902841A1 (enExample)
HK (1) HK1214652A1 (enExample)
WO (1) WO2014160499A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096785A1 (en) * 2014-12-19 2016-06-23 F. Hoffmann-La Roche Ag Identification of transglutaminase substrates and uses therefor
US10006915B2 (en) 2014-12-19 2018-06-26 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US11054425B2 (en) 2014-12-19 2021-07-06 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE534415T1 (de) 2005-12-13 2011-12-15 Harvard College Gerüste zur zelltransplantation
EP3851856A3 (en) 2007-03-27 2021-11-03 Immunovia AB Method, array and use thereof
SI2624873T1 (sl) 2010-10-06 2020-07-31 President And Fellows Of Harvard College Injektabilni, pore-formirajoči hidrogeli za celične terapije - na osnovi materialov
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
JP2014526682A (ja) 2011-09-12 2014-10-06 クリエイティクス エルエルシー 標的分子を検出する非侵襲的方法
EP2836512B1 (en) 2012-04-11 2018-10-24 F.Hoffmann-La Roche Ag Improved antibody light chains
EP3662896B1 (en) 2012-04-16 2024-02-28 President and Fellows of Harvard College Mesoporous silica compositions for modulating immune responses
MX360236B (es) 2012-06-27 2018-10-26 Berg Llc Uso de marcadores en el diagnostico y tratamiento de cancer de prostata.
JP6184581B2 (ja) 2013-03-15 2017-08-23 シャイア バイロファーマ インコーポレイテッド Ｃ１エステラーゼ抑制因子欠乏に関連する障害の予防及び治療のためのｃ１−ｉｎｈ組成物ならびに方法
JP6652916B2 (ja) * 2013-06-20 2020-02-26 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 膵臓がんを診断するための方法
JP6759104B2 (ja) 2014-04-04 2020-09-23 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ 精密分子質量を用いた免疫グロブリンのアイソタイピング
JP7348708B2 (ja) 2014-04-30 2023-09-21 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 組み合わせワクチン装置および癌細胞を殺滅する方法
WO2015182218A1 (ja) * 2014-05-26 2015-12-03 オリンパス株式会社 膵癌判定方法
KR20160045547A (ko) * 2014-10-17 2016-04-27 에스케이텔레콤 주식회사 췌장암 진단용 조성물 및 이를 이용한 췌장암 진단방법
SG10202012249YA (en) 2014-12-08 2021-01-28 Berg Llc Use of markers including filamin a in the diagnosis and treatment of prostate cancer
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
US20160271120A1 (en) * 2015-03-17 2016-09-22 Oakdene Holdings Llc Pharmaceutical composition for cleansing of the gastrointestinal tract
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
WO2016164593A1 (en) * 2015-04-07 2016-10-13 President And Fellows Of Harvard College Compositions and methods for modulating hydroxylation of acc2 by phd3
WO2016164705A1 (en) 2015-04-10 2016-10-13 Omar Abdel-Rahman Ali Immune cell trapping devices and methods for making and using the same
EP3286218B1 (en) * 2015-04-20 2022-11-30 Consejo Superior de Investigaciones Cientificas Agents binding specifically to human cadherin-17, human cadherin-5, human cadherin-6 and human cadherin-20 rgd motif
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
HK1254866A1 (zh) 2015-06-25 2019-07-26 Immatics Biotechnologies Gmbh 用於骨髓瘤和其他癌症免疫治疗的新型细胞表位和细胞表位组合物
WO2017036369A1 (en) * 2015-09-03 2017-03-09 The University Of Hong Kong A monoclonal antibody for predicting tamoxifen response in breast cancer patients
CN105296613A (zh) * 2015-09-24 2016-02-03 郑州市职业病防治院 一种人TERF1基因rs3863242位点多态性检测技术
CN108026164A (zh) 2015-09-24 2018-05-11 梅约医学教育与研究基金会 通过质谱鉴定免疫球蛋白游离轻链
WO2017095632A1 (en) * 2015-11-30 2017-06-08 Mayo Foundation For Medical Education And Research Heatr1 as a marker for chemoresistance
CN105785013A (zh) * 2016-04-21 2016-07-20 卢连伟 一种辅助检测胰腺癌的胶体金免疫层析试纸及其制备方法
GB201608192D0 (en) * 2016-05-10 2016-06-22 Immunovia Ab Method, array and use thereof
JP7075125B2 (ja) * 2016-05-25 2022-05-25 イマティクス バイオテクノロジーズ ゲーエムベーハー 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ
CN109789092A (zh) 2016-07-13 2019-05-21 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
CA3032505A1 (en) 2016-08-02 2018-02-08 President And Fellows Of Harvard College Biomaterials for modulating immune responses
CN109863395B (zh) 2016-09-07 2023-05-23 梅约医学教育与研究基金会 分子量法鉴定和监测裂解免疫球蛋白
CN107655985B (zh) * 2017-08-25 2020-05-26 南京农业大学 一种基于lc-ms-ms技术的体内蛋白质营养的评价方法
US12153052B2 (en) 2017-09-13 2024-11-26 Mayo Foundation For Medical Education And Research Identification and monitoring of immunoglobulin J chains
US11946937B2 (en) 2017-09-13 2024-04-02 Mayo Foundation For Medical Education And Research Identification and monitoring of apoptosis inhibitor of macrophage
AU2019247747A1 (en) * 2018-04-03 2020-09-24 Creatics Llc Methods for cancer detection by evaluation of glycan-binding patterns of immunoglobulins in gastrointestinal lavage fluid samples
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020101878A2 (en) * 2018-10-29 2020-05-22 The Johns Hopkins University Rasopathy treatment
WO2020223646A1 (en) * 2019-05-02 2020-11-05 Creatics Llc Methods for cancer detection by evaluation of alpha-1-antitrypsin (aat) and chymotrypsin-like elastase in gastrointestinal lavage fluid samples
US20220251625A1 (en) * 2019-06-24 2022-08-11 Urteste S.A. Novel diagnostic marker for pancreatic cancer
JP2022549270A (ja) 2019-09-23 2022-11-24 プレジデント アンド フェローズ オブ ハーバード カレッジ バイオマテリアルベースの無抗原ワクチンおよびその使用
US20220397576A1 (en) * 2019-10-18 2022-12-15 Reccan Diagnostics Ab Apparatuses and methods for detection of pancreatic cancer
JP7693718B2 (ja) * 2020-05-26 2025-06-17 エフ． ホフマン－ラ ロシュ アーゲー 定量器－確認器比チェックのために顧客質量分析機器を較正するためのコンピュータ実装方法
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
KR102448586B1 (ko) * 2020-10-08 2022-09-27 가톨릭대학교 산학협력단 췌장암 환자의 항암제 치료 반응성 예측용 마커
CN112461915B (zh) * 2020-12-08 2024-07-12 杭州汇健科技有限公司 一种与药物敏感相关的特征分子筛选、药敏程度检测、细胞亚型检测的方法
WO2022125482A1 (en) * 2020-12-08 2022-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス，インク． 結腸細胞増殖障害の早期検出のためのマーカー
US20240229154A9 (en) * 2021-02-12 2024-07-11 Institut National de la Santé et de la Recherche Médicale Method for prognosis and treating a patient suffering from cancer
US20240201166A1 (en) * 2021-04-11 2024-06-20 Vikas Khurana Diagnosis and treatment of congestive colon failure (ccf)
CA3221544A1 (en) * 2021-06-07 2022-12-15 Adrienne Marie Rothschilds Compositions and methods for targeted delivery of therapeutic agents
US12152280B2 (en) 2021-09-20 2024-11-26 Droplet Biosciences, Inc. Drain fluid for diagnostics
WO2023044117A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Drain fluid for diagnostics
US12416626B2 (en) 2022-07-22 2025-09-16 Droplet Biosciences, Inc. Methods for evaluating candidate therapy efficacy based on changes in lymphatic fluid biomarkers
WO2024086298A2 (en) * 2022-10-20 2024-04-25 The Johns Hopkins University Hla class i and class ii-restricted t-cell epitopes in pancreatic cancer tissues and uses thereof
WO2024206856A2 (en) * 2023-03-30 2024-10-03 Thomas Jefferson University Dna-dependent synthesis of rna by dna polymerase theta variants

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114818B1 (en) * 1982-08-09 1987-08-12 Centocor, Inc. Immunoassay for carbohydrate antigenic determinant
JPH0673470B2 (ja) * 1986-07-15 1994-09-21 協和醗酵工業株式会社 抗ヒト胃癌単クロ−ン性抗体ａｍｃ−４６２
US5359681A (en) 1993-01-11 1994-10-25 University Of Washington Fiber optic sensor and methods and apparatus relating thereto
US6924153B1 (en) 1997-03-06 2005-08-02 Quidel Corporation Quantitative lateral flow assays and devices
JPH11225800A (ja) * 1998-02-10 1999-08-24 Kureha Chem Ind Co Ltd 体液を用いた癌検出方法及びキット
US6447763B1 (en) * 1998-06-12 2002-09-10 Ian L. Gordon Method and system for production and collection of lavage induced stool (LIS) for chemical and biologic tests of cells
EP1298205A4 (en) * 2000-07-03 2004-06-16 Mochida Pharm Co Ltd NEW LIPASE
WO2003014298A2 (en) * 2001-08-03 2003-02-20 Origene Technologies, Inc. Full-length prostate selective polynucleotides and polypeptides
US7291324B2 (en) * 2002-10-22 2007-11-06 Braintree Laboratories Inc. Method of bowel cleansing
WO2004055519A2 (en) * 2002-12-17 2004-07-01 Sinogenomax Co. Ltd. Specific markers for pancreatic cancer
EP1718192A4 (en) * 2003-11-26 2010-07-14 Dana Farber Cancer Inst Inc ANIMAL MODELS FOR THE ADENOCARCINOM OF PANCREAS AND USES THEREOF
EP1766412B1 (en) 2004-05-21 2009-04-01 The Institute for Systems Biology Compositions and methods for quantification of serum glycoproteins
JP2009528507A (ja) 2006-03-02 2009-08-06 オンコセラピー・サイエンス株式会社 Ｒｅｇ４タンパク質を用いて膵癌を診断する方法
ES2522542T3 (es) * 2008-02-15 2014-11-17 Mayo Foundation For Medical Education And Research Detección de neoplasia a partir de una muestra de heces
US20090258090A1 (en) 2008-04-11 2009-10-15 Braintree Laboratories, Inc. Colon cleansing solution
JP5312684B2 (ja) * 2009-05-04 2013-10-09 エフ．ホフマン−ラ ロシュ アーゲー 癌のマーカーとしてのｄｐｐｉｖ／セプラーゼの使用
WO2011027311A2 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
JP2013510094A (ja) * 2009-11-05 2013-03-21 ユニバーシティ オブ バージニア パテント ファウンデーション がんのバイオマーカーとしてプレクチン−１を検出するための組成物および方法
EP3355057A3 (en) * 2010-06-01 2018-12-12 Metanomics Health GmbH Means and methods for diagnosing pancreatic cancer in a subject
MX350533B (es) * 2010-08-13 2017-09-08 Somalogic Inc Biomarcadores de cancer pancreatico y usos de los mismos.
AU2011351990A1 (en) * 2010-12-29 2013-07-18 Expression Pathology, Inc. Protein biomarkers of recurrent breast cancer
JP5984795B2 (ja) * 2011-04-05 2016-09-06 オリンパス株式会社 膵疾患を検出するためのデータを収集する方法
JP2014526682A (ja) * 2011-09-12 2014-10-06 クリエイティクス エルエルシー 標的分子を検出する非侵襲的方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016096785A1 (en) * 2014-12-19 2016-06-23 F. Hoffmann-La Roche Ag Identification of transglutaminase substrates and uses therefor
US10006915B2 (en) 2014-12-19 2018-06-26 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US10788495B2 (en) 2014-12-19 2020-09-29 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US11054425B2 (en) 2014-12-19 2021-07-06 Roche Sequencing Solutions, Inc. System and method for identification and characterization of transglutaminase species
US11268120B2 (en) 2014-12-19 2022-03-08 Roche Sequencing Solutions, Inc. Identification of transglutaminase substrates and uses therefor

Also Published As

Publication number Publication date
WO2014160499A2 (en) 2014-10-02
EP2972375A2 (en) 2016-01-20
JP2016519285A (ja) 2016-06-30
JP2022141755A (ja) 2022-09-29
US20160033511A1 (en) 2016-02-04
US20220128563A1 (en) 2022-04-28
AU2022224782A1 (en) 2022-09-22
US20190234951A1 (en) 2019-08-01
HK1214652A1 (zh) 2016-07-29
AU2020202066B2 (en) 2022-06-02
AU2020202066A1 (en) 2020-04-09
JP7109008B2 (ja) 2022-08-10
JP2020091295A (ja) 2020-06-11
WO2014160499A3 (en) 2015-01-29
AU2014243704A1 (en) 2015-09-10
JP6646571B2 (ja) 2020-02-14

Similar Documents

Publication Publication Date Title
AU2020202066B2 (en) Methods and compositions for detecting pancreatic cancer
WO2007103770A2 (en) Compositions and methods for analyzing renal cancer
US20230063827A1 (en) Methods and Compositions for the Diagnosis of Ovarian Cancer
KR20090034961A (ko) 폐암 진단 검사
CA2680556A1 (en) Biomarkers of prostate cancer and uses thereof
Zhang et al. Contribution of biomarkers for pancreatic cancer-associated new-onset diabetes to pancreatic cancer screening
KR101388711B1 (ko) 암 진단 마커로서의 보체 ｃ９
EP3144676B1 (en) Kit comprising antibody specifically binding to complement factor b protein and antibody specifically binding to carbohydrate antigen 19-9 protein for diagnosing pancreatic cancer
US20230145939A1 (en) Marker composition for cancer diagnosis or prognosis based on exosome overexressing gcc2
US20220196670A1 (en) Endometrial receptivity determination
US20200400673A1 (en) Methods for cancer detection by evaluation of glycan-binding patterns of immunoglobulins in gastrointestinal lavage fluid samples
US20130243757A1 (en) Method for cancer detection
KR100883530B1 (ko) 대장암 진단용 단백질 마커 아데노실호모시스테이나제 및이에 대한 항체를 포함하는 대장암 진단키트
JP4795353B2 (ja) 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素１（ｃｐｓ１）の使用
US20150004621A1 (en) Biological marker for early cancer detection and methods for cancer detection (bf819)
KR101994821B1 (ko) 포크머리상자 o 3 단백질의 용도
KR20180117918A (ko) Mfap5 측정 제제를 포함하는 대장암 진단용 조성물, 키트, 및 이를 이용한 대장암 진단 방법
US20250334576A1 (en) MARKER FOR CANCER DETECTION (BC / or BF9)
Yue et al. Preliminary proteomic analysis of human tears in lacrimal adenoid cystic carcinoma and pleomorphic adenoma
KR102128251B1 (ko) 아르기닌이 메틸화된 drd2에 특이적으로 결합하는 대장암 진단용 바이오마커 조성물
WO2022091793A1 (ja) 糞便由来タンパク質を用いた膵臓がんバイオマーカーの開発
Du et al. Abnormal N-glycosylated CPXM1 promotes gastric cancer metastasis through ITGB2/FAK pathway
AU2014203702B2 (en) New tumor marker
KR20080092490A (ko) 대장암 진단용 단백질 마커 켈그라눌린 ａ와 켈그라눌린 ｂ및 이들 각각에 대한 항체를 포함하는 대장암 진단키트
HK1166329B (en) New tumor marker

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190304

FZDE Discontinued

Effective date: 20220426

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDC Discontinued application reinstated

Effective date: 20220721

FZDE Discontinued

Effective date: 20240228